替比鸟嘌呤与低剂量硫嘌呤联合别嘌醇在IBD中的安全性比较
本研究比较了替比鸟嘌呤与低剂量硫嘌呤联合别嘌醇(LDTA)在因不良事件停用传统硫嘌呤的炎症性肠病(IBD)患者中的安全性。共纳入182例患者(替比鸟嘌呤94例,LDTA 88例),中位随访104周。两组因不良事件停药率均为19%左右,校正混杂因素后,停药率、不良事件、感染、住院及临床缓解均无显著差异。
要点
- 因不良事件停用传统硫嘌呤的IBD患者中,替比鸟嘌呤与LDTA因不良事件停药率相似(约19%)。
- 校正混杂因素后,两种治疗在不良事件、感染、住院和临床缓解方面均无显著差异。
- 在升级至生物制剂前,可考虑替比鸟嘌呤或LDTA两种方案。
核心结论
- 在因不良事件停用传统硫嘌呤的IBD患者中,替比鸟嘌呤与LDTA因不良事件停药率均为19%,两组安全性及疗效无显著差异。
研究设计与样本
- 前瞻性ICC注册研究中接受LDTA的患者与三所大学医院接受替比鸟嘌呤的患者比较,排除合用生物制剂者,共纳入182例(替比鸟嘌呤94例,LDTA 88例),中位随访104周(IQR 91-104)。
主要发现
- 替比鸟嘌呤组因不良事件停药20%,LDTA组18%。
- 校正混杂因素后,因不良事件停药无差异(OR 0.50,95%CI 0.15-1.68,P=0.26)。
- 不良事件(OR 0.89,95%CI 0.44-1.81,P=0.75)、感染(OR 1.05,95%CI 0.40-2.73,P=0.93)、住院(OR 2.00,95%CI 0.64-6.23,P=0.23)均无显著差异。
- 104周临床缓解(医师整体评估=0)无差异(OR 0.74,95%CI 0.33-1.68,P=0.48)。
- 倾向性评分匹配队列结果与上述一致。
关键数值与推荐
- 主要结局为因不良事件停药,替比鸟嘌呤组20%,LDTA组18%。
- 次要结局包括安全性结局及104周无手术、无生物制剂、无激素的临床缓解。
临床怎么用
- 对于因不良事件无法耐受传统硫嘌呤的IBD患者,替比鸟嘌呤或LDTA均可考虑作为升级至生物制剂前的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both tioguanine and low-dose thiopurines combined with allopurinol (LDTA) can be considered for the treatment of inflammatory bowel disease (IBD) when conventional thiopurines fail due to adverse events. AIM: To compare the safety of tioguanine and LDTA in IBD patients. METHODS: Inflammatory bowel disease patients who failed conventional thiopurines due to adverse events and initiated LDTA in standard care were identified in the prospective ICC Registry. IBD patients who failed conventional thiopurines due to adverse events and initiated tioguanine were enrolled in three university hospitals. Patients on concomitant biologicals were excluded. The primary outcome was discontinuation of therapy due to adverse events. Secondary outcomes included: safety outcomes and surgery-, biological- and corticosteroid-free clinical remission (physician global assessment = 0) after 104 weeks. Both multiple logistic regression and propensity score matching were used to correct for confounders. RESULTS: In total, 182 IBD patients treated with tioguanine (n = 94) or LDTA (n = 88) were included with a median follow-up of 104 weeks (IQR 91-104). Of these, 19% (tioguanine: 20%, LDTA: 18%) of patients discontinued therapy due to adverse events. After adjusting for confounders, there were no differences in terms of discontinuation rate due to adverse events (OR 0.50, 95% CI 0.15-1.68, P = 0.26), adverse events (OR 0.89, 95% CI 0.44-1.81, P = 0.75), infections (OR 1.05, 95% CI 0.40-2.73, P = 0.93), hospitalisations (OR 2.00, 95% CI 0.64-6.23, P = 0.23) or clinical remission (OR 0.74, 95%CI 0.33-1.68, P = 0.48). All results are comparable with the propensity score matched cohort. CONCLUSION: Nineteen percent of IBD patients with prior failure to conventional thiopurines due to adverse events discontinued therapy with tioguanine or LDTA due to adverse events. Either therapy may be considered before escalating to biological therapy.
引用
- Biemans VBC, Savelkoul E, Gabriëls RY, et al. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2020. PMID: 32339331. doi:10.1111/apt.15730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。